Cannabis Law Report

JULY 24, 2019

It will be the first to have meaningful and consistent data of how medicinal cannabis has helped when properly prescribed as part of a full treatment pathway.” There are concerns about the evidence base for the prescription of medicinal cannabis products containing THC to children in terms of both efficacy and possible future harm.

Epilepsy

Leaf Science

JULY 23, 2019

In the UK, cannabis was legalized for medicinal purposes in 2018 which saw patients of epilepsy and multiple sclerosis able to access pharmaceutical cannabis derivatives such as Sativex and Epidiolex. We shall look into what these benefits may be and what the science do we have that backs this up. Medicinal cannabis in the western world.

Strains

Cannabis Law Report

JANUARY 13, 2020

Advance the medical literature regarding Epidiolex through publications in top-tier medical journals and at major scientific and medical meetings, notably the American Academy of Neurology and American Epilepsy Society meetings. Media Enquiries: Sam Brown Inc. media enquiries. Enquiries: GW Pharmaceuticals plc. Christy Curran.

Pharmaceutical

Cannabis Law Report

MAY 6, 2022

The FDA’s warning letters tell the public that the FDA reads and reviews companies’ websites, labels, social media, and marketing language. The FDA evaluates sellers’ claims, graphics, and product descriptions – including products marketed for animals, information about food additives, and social media websites.

THC

Cannabis Law Report

NOVEMBER 24, 2021

Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. At the same time, the outlook on cannabis research data is largely positive. Refractory paediatric epilepsy. Background. Cancer pain.

Research and Development

Cannabis Law Report

JULY 12, 2019

As reported in the Guardian, Analytical Cannabis emphasises the importance of this for those suffering from conditions such as chronic pain, epilepsy and neurological and psychiatric disorders who have long been seeking access to what they hope is a transformative medicine.

Epilepsy

Puff Puff Post

MARCH 2, 2020

Source: New Frontier Data). · Domestic quotas represent a further milestone in the Company’s stated timeline to bring the first medical cannabis products to market in Colombia, targeting patients with two priority conditions; chronic pain and nausea associated with chemotherapy. SOURCE Khiron Life Sciences Corp. Web Site: [link].

Extraction

Cannabis Law Report

DECEMBER 20, 2021

Data To Support Regulatory Filings in the United States. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of epilepsy in children (a rare pediatric disease) and adults. Media: Laura Radocaj. BERWYN, Pa.–(BUSINESS

Clinical Trials

Cannabis Law Report

SEPTEMBER 13, 2021

Positive data from this important study would significantly advance MYMD-1’s potential to become a blockbuster drug for inflammation and aging.”. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Media: media@mymd.com. Chief Scientific Officer.

Clinical Trials

Cannabis Law Report

JANUARY 27, 2020

The US Food and Drug Administration (FDA) asserts its case clearly on its website, emphasising that it has approved only one product, and that’s a prescription drug to treat two rare forms of epilepsy. It appeared comprehensive and relied on data mainly from food authorities but also from industry. Alarm 2: EFSA, EU.

Safety

Cannabis Law Report

DECEMBER 8, 2021

This data should strengthen the Company’s IND filing in advance of the anticipated start of first-in-human clinical trials. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of epilepsy in children (a rare pediatric disease) and adults.

Clinical Trials

Puff Puff Post

MARCH 2, 2020

Source: New Frontier Data). · Domestic quotas represent a further milestone in the Company’s stated timeline to bring the first medical cannabis products to market in Colombia, targeting patients with two priority conditions; chronic pain and nausea associated with chemotherapy. SOURCE Khiron Life Sciences Corp. Web Site: [link].

Extraction

Greenspoon Marder Cannabis Law Group Blog

APRIL 2, 2019

For example, we’re seeking comments, data and information on a variety of topics including: what levels of cannabis and cannabis-derived compounds cause safety concerns; how the mode of delivery (e.g.,

CBD

Cannabis Law Report

NOVEMBER 10, 2021

Once the Envelta IND-enabling studies are submitted to the FDA, the data may be cross-referenced to our cancer pain and PTSD INDs. Media: Laura Radocaj. About Virpax Pharmaceuticals. MET technology is also used in AnQlar™, a candidate to inhibit viral replication caused by influenza or SARS-CoV-2. Forward-Looking Statement.

Research and Development

MMJ Recs

MAY 3, 2024

Analyzing data on patient demographics, medical conditions, and treatment preferences can help stakeholders identify emerging trends and tailor services to meet evolving patient needs. Legal professionals can guide navigating legal issues and protecting patients’ rights.

Marijuana

Cannabis Law Report

JANUARY 20, 2022

Media and Investor Contacts For Eleusis: Alex Speiser, Corporate Development Director. Media: Alan Oshiki and Will Braun, Abernathy MacGregor. You may obtain free copies of these documents as described in the preceding paragraph. Email: alexander.speiser@eleusisltd.com. Bill@silverspikecap.com 212-905-4933.

Therapy

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? PDF Version.

Pharmaceutical

Cannabis Law Report

SEPTEMBER 1, 2022

The CUP’s current list of qualifying conditions includes cancer, PTSD, epilepsy and hundreds of neurodegenerative diseases but excludes the many other patients who could benefit from the proven power of medical cannabis to treat chronic pain. “The data is clear. For Media Inquiries Only: Callie Neatherlin. 512-439-9720.

Chronic Pain

CannaMD

AUGUST 19, 2020

Our initial data suggest that some C. Note: Study extracts were applied via media. 2) A 2020 study found that CBD can inhibit the production of proinflammatory cytokines that have been associated with SARS-CoV2 induced multi-organ pathology and mortality. Our results lay a foundation for further in-depth analysis of the effects of C.

Research and Development

Cannabis Law Report

AUGUST 31, 2022

The CUP’s current list of qualifying conditions includes cancer, PTSD, epilepsy and hundreds of neurodegenerative diseases but excludes the many other patients who could benefit from the proven power of medical cannabis to treat chronic pain. The data is clear. For Media Inquiries Only: Callie Neatherlin.

Chronic Pain

Cannabis Law Report

NOVEMBER 26, 2019

Many unanswered questions and data gaps about CBD toxicity exist, and some of the available data raise serious concerns about potential harm from CBD. The FDA has not approved any CBD products other than one prescription human drug product to treat rare, severe forms of epilepsy.

Safety

StrainConnect

FEBRUARY 8, 2019

From cancer(11) to epilepsy(12), there seems to be very little that cannabis cannot help with. Endocannabinoids and epilepsy - Science Direct. Please email support@strainconnect.com or try us on social media. Dont modify these 3 pswp__item elements, data is added later on. -->. How is CBD really helpful? NCBI - NIH.

Hemp